Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study of Pembrolizumab and Cryoablation in People With Mesothelioma

ClinicalTrials.gov ID: NCT05071014

Public ClinicalTrials.gov record NCT05071014. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of Pembrolizumab Plus Cryoablation in Patients With Unresectable Mesotheliomas

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The researchers are doing this study to find out whether the combination of pembrolizumab and cryoablation is a safe treatment that causes few or mild side effects in people with mesothelioma. The researchers will also look at whether the combination of pembrolizumab and cryoablation is effective against participants' cancer.

Study identification

NCT ID
NCT05071014
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Enrollment
2 participants

Conditions and interventions

Interventions

Drug · Procedure

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 24, 2021 (Actual)
Primary completion
Dec 18, 2023 (Actual)
Completion
Dec 18, 2023 (Actual)
Last update posted
Dec 20, 2023

2021 – 2023

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
7
Facility City State ZIP Site status
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey 07920 —
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748 —
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey 07645 —
Memorial Sloan Kettering Commack (Limited protocol activities) Commack New York 11725 —
Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York 10604 —
Memorial Sloan Kettering Cancer Center (All protocol activities) New York New York 10065 —
Memorial Sloan Kettering Nassau (Limited protocol activities) Uniondale New York 11553 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05071014, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 20, 2023 · Synced Nov 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05071014 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →